Theralase Technologies Inc. V.TLT

Maybe....

[skier59]

we can get to try on early stage cancer, instead of the leftover, beat up, that nobody has any success treating !!!!!!!!!

[skier59]

I'm confident our treatment would wipe out the need for BCG. Front line, first option.

[Rumpl3StiltSkin]

I think they would need a new Phase 1 +2 +3 for that.

[fredgoodwinson]

Yes skier a long term moan of mine subsequent to reading the Clinical Protocol given evident potential from preclinical results to become huge as standard of care monotherapy in early stage disease. Other far less compelling drugs were being trialled ab initio in that setting - why not ours? Instead TLD-1433 was asked to piss through the eye of a needle in Phase IB.Fortunately (and after

[gojotv!]

To say nothing of the stellar success rates I expect will result from third, fourth, and even fifth treatments when this is commercialized...! 100% Complete Response in all tumerous cancer indications, here we come! GLTA!... and I mean "ALL"!!  

[ScienceFirst]

Skier59 ... The partner we'll team up with will indeed want to position TLD-1433 in other NMIBC early stage indications and also other sub-diseases (papillary, etc ...), not to mention MIBC so they can completely dominate the bladder cancer indication. Then, they will want to advance TLD-1433 in other oncology indications preclinically tested by TLT.   And if they're wise, they will

[skier59]

I think we all know and feel that once we get the chance to treat NMIBC in the early stages, prior to patients going through all the other carp, our CR rates will jump up dramatically. It's sad that our SP gets knocked down on such low volume, but that's been going on for many many years. I think those days are soon coming to a close, and the next 6 months should be exciting for us ! Like

[LaserStock29]

Can we get the BTD and AA in one go or will these next 6 months turn into Apply in 4Q 2022 for BTD then  Apply for AA in 1Q 2023 So by June 2023 we can just start to commercially get this going. BTW Endocyte didnt' even get into Phase 3 before Novartis started negotiations.  Endocyte + Novartis Endocyte looked set to spend the next year or so working toward phase 3 data before

[Lesalpes29]

Good post. Roger has 7M+ shares. I think it's enough to make him move forward. SP is a shame but the SP is not the company.

[Rumpl3StiltSkin]

LS, I think once we apply for BTD, which should/could happen as soon as we have some compelling data. That the AA application will follow shortly. It is estimated that AA is approved in aprox 6 mos if a company has FT. BTD I think should get us AA approval as quickly as 1 month. Probably 2-3 tho. So it depends on how quickly the BTD process takes to apply for and get approved for...

[Lesalpes29]

It's a turning point for this story in the coming weeks. And a positive one. Added at .355, probably my last prurchase! Novartis youhou!

[Longholder99]

One of the things I think we are waiting for is Roger's return as CEO. The meaningless cold laser complaint and its long lasting effects are almost over too. There is always more to the story. I forget when he has paid his dues on the restrictions from the Board. But its soon.

[Gooseybear]

Is his wife also involved with management of the company? Also, how do you feel about the Board makeup? Voting on TLTF now open.

[skys1]

Goosey, The CFO is Kristina Hachey, is Roger's wife. 

[Oilminerdeluxe]

January first? I might be wrong though, so don't take my word for it.

[CAinPlap]

Some time in February 2023 his supension ends. By March 1, 2023, he will likely be CEO. Not sure Kristina would be CFO without her "influence" with Roger. My only complaint with her would be the less than stellar attempts to raise funds before the last financing.

[Gooseybear]

Thanks CA. I'd need to do some research on the Board makeup in terms of their work backgrounds in the biotechnology arena. I recall some of them previously had little to no experience. I'm a longtime holder but get a little concerned when I see personal relationships in senior management ranks.